Aug 23, 2012
After years of nothing new in herpes research, everything is new right now. Nationally, there are at least three different studies beginning for the treatment of genital herpes. First, the Genocea phase one (first in humans) trial. Instead of an oral medication to treat herpes, Genocea out of Boston has taken the approach of stimulating the immune system to respond more robustly to the herpes virus in people who are already infected with the virus. The routinely available oral medicines interfere with replication of the virus, but this treatment is designed to allow the immune system to respond more effectively to the virus and subsequently reduce the frequency of recurrences and reduce viral shedding. This phase 1 study is being conducted at several sites in the US. For more information contact Jessica Rowlands at Feinstein Kean Healthcare, 202-729-4089.
The next research study is sponsored by AiCuris, a German company. This is a phase 2 trial, the phase 1 trial complete two years ago. The results of the phase 1 trial indicate that this oral medicine has excellent activity against the herpes virus. The newest study will compare the AiCuris drug against Valtrex, an FDA approved medicine for the treatment of genital herpes. For more information about research sites conducting this study, please contact AiCuris. Information Email: info-at-aicuris-dot-com
Finally, another therapeutic vaccine trial starting in October from a company called Agenus. This is another attempt at enhancing the immune response to herpes as a way to decrease the frequency of recurrences and viral shedding for people already infected with HSV 2. For site locations as well as additional study information, you can contact Westover Heights Clinic in Portland, Oregon at: westoverheights.com.
After years of nothing much new in the genital herpes treatment scene, we have three exciting new prospects for treating this challenging STD.
Terri Warren, RN, ANP
Westover Heights Clinic
2330 NW Flanders, Suite 207
Portland, OR 97210